http://www.enterpriseeuropeeast.org.uk/eox/assets/images/sitelook/een.gif Mon, 30 Aug 2010 00:00:00 GMT Technology collaboration - 10 TR 99PB 3IF0 OFFER

A company based in Turkey offers patented technology for cancer therapy. The treatment is targeted to a fundamental vulnerability of tumour cells identified by the founder of company and has been shown in phase II clinical investigations to safely eliminate tumour cells from patients irrespective of organ of origin and stage of tumour. Joint venture, technical cooperation and other agreements will be explored towards regulatory approval and marketing. Licensing is possible for certain areas.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 TR 99PB 3IF0&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 TR 99PB 3IF0&EnquiryType=BBS Thu, 19 Aug 2010 00:00:00 GMT Technology collaboration - 10 NL 60AF 3GNG OFFER

Protein-linked glycans regulate many biological processes. O-glycosylation is a.o. important in mucosal secretion, N-glycosylation in the folding of proteins. Conventional labelling of N-glycans produces the toxic hydrogen cyanide gas, while labelling of O-glycans is slow and requires expensive equipment. A Dutch Medical center has developed, a non toxic labelling process for N-glycans and a faster simpler labelling method for O-glycans. A commercial partner is sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3GNG&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3GNG&EnquiryType=BBS Thu, 19 Aug 2010 00:00:00 GMT Technology collaboration - 10 NL 60AF 3H1Q OFFER

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a genetic condition causing brain damage gradually leading to dementia. Mutations in the NOTCH3 gene, lead to accumulation of misfolded NOTCH3 proteins in the brain, impairing vascular reactivity and cerebral blood flow. At a Dutch University a method is found to prevent misfolding of NOTCH3 proteins. Commercial partners with relevant expertise for further development and marketing are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1Q&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1Q&EnquiryType=BBS Fri, 6 Aug 2010 00:00:00 GMT Technology collaboration - 10 NL 60AF 3H1R OFFER

Tumours must re-route the local bloodvessels (angiogenesis) to ensure a ready supply of substances for growth. There has been a long search to identify inhibitors of this process. At a Dutch University it was discovered that the Tel/ETV6: CtBP complex is indispensable in forming new bloodvessels. Intervention in the interplay between Tel and CtBP offers new targets to prevent aberrant angiogenesis. Commercial partners with relevant expertise in development and marketing are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1R&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1R&EnquiryType=BBS Fri, 30 Jul 2010 00:00:00 GMT Technology collaboration - 10 HU 50S3 3HWB OFFER

A Hungarian small business is developing nanoparticles (NP) for antitumor medication (diagnosis, treatment). The advantage of the technology is that the treatment by the application of NP with incorporated antitumor drugs or contrast agents is only aimed at the damaged parts unlike chemotherapy. The NP are biodegradable and non toxic. The innovation results in significantly higher chance of recovery from tumorous diseases. The company is looking for investors, partners for further development.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 HU 50S3 3HWB&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 HU 50S3 3HWB&EnquiryType=BBS Fri, 30 Jul 2010 00:00:00 GMT Technology collaboration - 10 IT 55X5 3HRR REQUEST

The company, based in Italy intends to utilize their own electric sterilization apparatus to obtain the selective despondency of cellular populations in different liquids (water-blood-plasma). Therefore the company is in search of scientific collaborations with enterprises from the medical sector, research centres, laboratories and hospitals able to carry out numerous tests necessary to identify and catalogue frequencies to apply to the electric fields to break apart cell membranes.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IT 55X5 3HRR&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IT 55X5 3HRR&EnquiryType=BBS Thu, 29 Jul 2010 00:00:00 GMT Technology collaboration - 10 NL 60AF 3H1O OFFER

Human keratinocytes, infected with high-risk Human Papillloma Viruses (hrHPV), display a decreased capacity for type I interferon (IFN) and proinflammatory cytokines production, enabling virus to escape the immune system. Scientists at a Dutch University Medical Center have now identified a key regulatory enzyme that is overexpressed at the gene and protein level in hrHPV infected human keratinocytes. Biotech or pharmaceutical companies are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1O&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 NL 60AF 3H1O&EnquiryType=BBS Tue, 6 Jul 2010 00:00:00 GMT Technology collaboration - 10 SE 67CH 3HWC REQUEST

A Swedish SME, intending to submit a Eurostars proposal, is inviting a European SME as partner in a project to develop new methods for detection of cancer/autoimmune diseases. The company has developed a cost effective method for measuring abnormal cell division through a simple blood test, which is used for detection of tumors. The aim of the project is to integrate this technology with technology from the partner. The partner should be an SME developing drugs for cancer/autoimmune diseases.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 SE 67CH 3HWC&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 SE 67CH 3HWC&EnquiryType=BBS Mon, 5 Jul 2010 00:00:00 GMT Technology collaboration - 10 DE 0855 3HRY OFFER

A German biotech SME and a university-based partner developed a DNA microarray for the detection of genetic polymorphisms (SNP) that are known to cause a liver disease. The proprietary technology allows for cost-effective, efficient and reliable diagnosis of further SNP-based diseases (cardiovascular diseases, cancer etc.) or for companion diagnostic / pharmacogenetic purposes. The organisations are looking for partners to adapt this technology to these or comparable new fields of application.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 DE 0855 3HRY&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 DE 0855 3HRY&EnquiryType=BBS Fri, 2 Jul 2010 00:00:00 GMT Technology collaboration - 10 ES 27F4 3HSS OFFER

An Andalusian research group has developed a new composition for the prevention and treatment of pathological processes associated with cell proliferation and angiogenesis, such as cancer and artherosclerosis, which overcomes the toxicity problems associated to statins in the prior art. In particular, the new composition comprises a statin and an activating agent of vascular endothelium. The research group is looking for a licence or collaboration agreement for further development.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 ES 27F4 3HSS&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 ES 27F4 3HSS&EnquiryType=BBS Thu, 1 Jul 2010 00:00:00 GMT Technology collaboration - 10 IL 80EP 3HP3 REQUEST

An Israeli cancer diagnostics SME that is developing a cluster of high value novel tumor biomarkers for early detection, prognosis and monitoring of cancer, seeks a partnership with industrial In Vitro Diagnostics (IVD) companies or clinical and academic organizations to jointly develop a broader serum or molecular panels for early diagnosis, prognosis and monitoring of cancer.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IL 80EP 3HP3&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IL 80EP 3HP3&EnquiryType=BBS Thu, 1 Jul 2010 00:00:00 GMT Technology collaboration - 10 IL 80EP 3HP4 REQUEST

An Israeli cancer diagnostics SME that is developing a cluster of high value novel tumor biomarkers for early detection, prognosis and monitoring of cancer, seeks a partnership with players in the pharmaceutical industry specializing in Oncology Therapeutics to jointly develop companion diagnostics.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IL 80EP 3HP4&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 IL 80EP 3HP4&EnquiryType=BBS Thu, 1 Jul 2010 00:00:00 GMT Technology collaboration - 10 PL 61AJ 3HRI OFFER

A Polish research institute has developed a technology of manufacturing of the pharmaceutical product based on peptide HYNIC-Tyr3-octreotide in the novel pharmaceutical form of dry kit for preparation of 99mTc-Tektrotyd radiopharmaceutical. The product can be used in isotope diagnostics in oncology. The partners for technical cooperation, joint venture or manufacturing agreement are sought and also partners for further product development.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 PL 61AJ 3HRI&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 PL 61AJ 3HRI&EnquiryType=BBS Wed, 30 Jun 2010 00:00:00 GMT Technology collaboration - 09 DE 0855 3D8O OFFER

Researchers of a German University have developed new therapeutic agents for the treatment of neurological diseases such as dementia, depression, Parkinsonism and neuropathic pain; possibly also cancer and immune system disorders. They are based on novel, highly selective agonists binding to the sigma1 receptor, a protein particularly concentrated in certain regions of the central nervous system. The University is looking for industry partners for licensing or research collaboration.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=09 DE 0855 3D8O&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=09 DE 0855 3D8O&EnquiryType=BBS Fri, 25 Jun 2010 00:00:00 GMT Technology collaboration - 10 GB 45P2 3HLS OFFER

A North West region of the United Kingdom University has developed a self tracking implant (allowing for much more accurate knowledge of target position, hence lower radiation doses) to assist radiotherapy and is seeking an appropriate partner to take to market under licence.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HLS&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HLS&EnquiryType=BBS Thu, 24 Jun 2010 00:00:00 GMT Technology collaboration - 10 GB 45P2 3HFZ OFFER

A North West region of the United Kingdom University has developed a novel self assembling peptide hydrogel that can be used as a cell culture reagent and now is seeking to license the use of the peptide to suitable pharmacological and bio medical companies for inclusion in their research program.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HFZ&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HFZ&EnquiryType=BBS Wed, 16 Jun 2010 00:00:00 GMT Technology collaboration - 10 GB 44O7 3HKU OFFER

A London-based university has developed a novel class of anti-cancer drugs which show considerable promise in selectively killing cancer cells with minimal toxicity to normal cells, in a spectrum of major cancers, including those that have developed resistance to chemotherapy. The university are looking for a suitable development partner to enter into a licence and research support agreement for progression into Phase I/II clinical trials.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 44O7 3HKU&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 44O7 3HKU&EnquiryType=BBS Fri, 11 Jun 2010 00:00:00 GMT Technology collaboration - 10 GB 45P2 3HG5 OFFER

A North West region of the United Kingdom University has developed a drug based Gold compound for Cancer Treament and is seeking a suitable partner to take this to commercialization under license.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HG5&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HG5&EnquiryType=BBS Fri, 11 Jun 2010 00:00:00 GMT Technology collaboration - 10 GB 45P2 3HHC REQUEST

A North West region of the United Kingdom SME has invented and developed a completely new cost effective, large sized and very robust form of radiation detectors. The developer is looking for a suitable partner to include the detector design in radiation detection/use equipment and take to market under either a license or as a collaborative joint venture.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HHC&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 GB 45P2 3HHC&EnquiryType=BBS Wed, 2 Jun 2010 00:00:00 GMT Technology collaboration - 10 FR 33k1 3HAK OFFER

French applied research center has developed a new class of Cell Penetrating Peptides (CPP) useful as carrier peptides for the delivery of various cargoes into cells. This class is able to cross the plasma membrane to reach its intracellular target. These derivatives have been synthesized and offer translocation property without presenting undesirable pharmacological effects. This new CPP is probably one of the best approaches to succeed in this area. Partners for industrialization are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 FR 33k1 3HAK&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 FR 33k1 3HAK&EnquiryType=BBS Thu, 27 May 2010 00:00:00 GMT Technology collaboration - 09 NL 60AF 3FT4 OFFER

Researchers at a Dutch University have developed a class of novel amphiphilic polypeptide block copolymers. The copolymers self-assemble into polymersomes which can be used as targeted drug delivery vehicles. The unique advantages of the technology includes: 1) the ease with which the copolymers are synthesized, and 2) the ability to precisely vary the thickness of the polymersome membrane and surface chemistry. The University is looking for partners active in drug delivery for licensing.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=09 NL 60AF 3FT4&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=09 NL 60AF 3FT4&EnquiryType=BBS Fri, 21 May 2010 00:00:00 GMT Technology collaboration - 10 EE 21B9 3HGB OFFER

An Estonian SME has developed a set of protein binding assays that enable to test ability of a certain protein to bind another specific protein or type of cells. The tests can be useful for researchers who study proteins (protein-protein interactions, protein's binding characteristics, protein's interactions with cell surface etc). Partners for testing of existing methods with new proteins and for development of new binding methods are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGB&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGB&EnquiryType=BBS Fri, 21 May 2010 00:00:00 GMT Technology collaboration - 10 EE 21B9 3HGD OFFER

An Estonian SME offers a method to evaluate the effect of compounds of interest to the growth of tumors of human origin in mice. A set of different human tumor cell lines can be used to induce subcutaneous tumor growth in mice which can be observed and treated thereafter. The tests can be useful for researchers studying cancer. Partners for testing of existing methods with new compounds and for development of new xenograft methods are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGD&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGD&EnquiryType=BBS Fri, 21 May 2010 00:00:00 GMT Technology collaboration - 10 EE 21B9 3HGE OFFER

An Estonian SME has developed a method to identify receptors/interactors of the protein of interest. A set of different approaches enable to catch and identify the unknown binding partner(s). The tests can be useful for researchers who study proteins (protein-protein interactions, protein's interactions with cell surface etc). Partners for testing of existing methods with new proteins and for development of new receptor identification methods are sought.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGE&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 EE 21B9 3HGE&EnquiryType=BBS Tue, 11 May 2010 00:00:00 GMT Technology collaboration - 10 ES 28G2 3H9E OFFER

A Spanish public research organisation has developed a magnetic nanoparticle which contains at least an active ingredient, which can be used for the treatment of cancer. It can be injected intravenously and targeted to the region of interest using an external magnetic field, thus presenting an optimal therapeutic concentration of the active ingredient in this region. Partners from the pharmaceutical industry are sought for the development and commercialization of the technology.]]> http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 ES 28G2 3H9E&EnquiryType=BBS http://www.enterpriseeuropeeast.org.uk/eox/services/enquire.asp?id=10 ES 28G2 3H9E&EnquiryType=BBS